BMJ15h
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Correspondence to Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden D-01307, Germany; martin.aringer{at}uniklinikum-dresden.de; Dr ...
BMJ1d
Genetics of rheumatoid arthritis: 2018 status
Study of the genetics of rheumatoid arthritis (RA) began about four decades ago with the discovery of HLA-DRB1. Since the beginning of this century, a number of non-HLA risk loci have been identified ...
BMJ5d
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent ...
BMJ4d
EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies
The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target ...
BMJ3d
Axial spondyloarthritis
Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic axSpA. It is a chronic inflammatory disease with a predilection for involving the axial skeleton. The most common ...
BMJ4d
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome
Objectives To develop a score for assessment of patients' symptoms in primary Sjögren's syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI). Methods Dryness, pain, somatic and mental fatigue ...
BMJ6d
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
Objective To investigate the association between baseline disease activity and the occurrence of flares after adalimumab tapering or withdrawal in patients with rheumatoid arthritis (RA) in sustained ...
BMJ5d
EULAR definition of difficult-to-treat rheumatoid arthritis
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...
BMJ6d
Examining the biological pathways underlying clinical heterogeneity in Sjogren’s syndrome: proteomic and network analysis
Objectives Stratification approaches are vital to address clinical heterogeneity in Sjogren’s syndrome (SS). We previously described that the Newcastle Sjogren’s Stratification Tool (NSST) identified ...
BMJ6d
Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications
Objective Autoantibodies against antigens carrying distinct post-translational modifications (PTMs), such as citrulline, homocitrulline or acetyllysine, are hallmarks of rheumatoid arthritis (RA). The ...
BMJ6d
Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis
Department of Rheumatology, Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, University of Tel Aviv, Israel Correspondence to: Dr O Elkayam, Department of Rheumatology, Tel ...
BMJ3d
OP0040 DOSE DEPENDENT MODULATION OF PROTEOMIC SIGNATURES BY IANALUMAB IN PATIENTS WITH SJÖGREN’S DISEASE
1 Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands 2 Department of Rheumatology and Clinical Immunology, ...